No Picture
Trading Ideas

Nissan names head of China business to be new CEO

Nissan has tapped the head of its China business, Makoto Uchida, as its new president and chief executive, to help lead a recovery from the leadership crisis and sinking profitability that followed the arrest of its former chairman, Carlos Ghosn, last year. Uchida is replacing Hiroto Saikawa, who resigned after acknowledging receiving dubious income. The Japanese automaker announced Uchida’s appointment late Tuesday in a hastily called half-hour news conference by board members Yasushi Kimura and Masakazu Toyoda. …read more […]

No Picture
Trading Ideas

Goldman Sachs: 3 Recession-Resistant Stocks to Buy

Less than a week ago, Goldman Sachs private wealth management chief investment officer Sharmin Mossavar-Rahmani stoked investor worries with a comment putting the chances of a recession hitting the U.S. in 2020 at somewhere between 25% and 30%.But less than a week later, Goldman global strategist Peter Oppenheimer seemed to say the opposite, telling CNBC: “This downturn in manufacturing has been one of the longest on record and may start to stabilize, if not improve, somewhat soon … Growth has slowed but [the economy] is not close to recession,” he concluded.And we have to say — this all seems terribly …read more […]

No Picture
Trading Ideas

Deutsche Bank's chairman best paid among German blue chips in 2018

Deutsche Bank’s Paul Achleitner was the best paid chairman of a German blue-chip company last year, according to a study published Tuesday. Achleitner earned almost 860,000 euros ($944,624.00), surpassing that paid to the chairmen of BMW and Fresenius by more than 200,000 euros, according to shareholder lobby group DSW. Achleitner, whose salary was 7.3% higher than a year earlier, ousted Deutsche’s chief executive in 2018, and the bank reported its first annual profit in four years. …read more […]

No Picture
Trading Ideas

UPDATE 1-Humira, Rituxan top list of U.S. drugs with biggest price increases -report

AbbVie Inc’s arthritis drug Humira and Roche Holding AG’s cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. The price hikes were more than twice the rate of medical inflation and were not supported by any new clinical evidence, the Institute for Clinical and Economic Review (ICER) said in the analysis. Other top treatments by spending that were called out included Pfizer Inc’s pain drug Lyrica, Gilead Sciences Inc’s HIV drug Truvada, Amgen Inc’s cancer drug …read more […]

No Picture
Trading Ideas

UPDATE 1-“Call of Duty: Mobile” smashes records with 100 mln downloads in first week

The mobile version of videogame franchise “Call of Duty” racked up 100 million downloads in its first week, industry site Sensor Tower said on Tuesday, dwarfing the debuts of previous smashes including “Fortnite” and “PlayerUnknown’s Battlegrounds” (PUBG). PUBG, Fortnite and Electronic Arts’ “Apex Legends” scored 26.3 million, 22.5 million and 25 million respectively in their first week of release. “This is by far the largest mobile game launch in history in terms of the player base that’s been built in the first week,” said Randy Nelson, head of mobile insights at Sensor Tower. …read more […]

No Picture
Trading Ideas

Nissan Picks New CEO to Lead Recovery From Ghosn Scandal

(Bloomberg) — Nissan Motor Co. named the head of its China joint venture as chief executive officer, as the Japanese carmaker looks to heal divisions caused by its former chairman’s arrest and repair fraught relations with partner Renault SA.Makoto Uchida, 53, will work alongside Ashwani Gupta from affiliate Mitsubishi Motors Corp., who was named chief operating officer while Jun Seki, the former chief of Nissan in China, will become deputy COO., the board said Tuesday.Nissan’s third boss in as many years will need to address deteriorating profits and strained relations with Renault as well as executing a massive restructuring.Nissan’s relationship …read more […]